Yan Yulan, Han Feng, Fu Huo, Xia Weiyi, Qin Xi
Department of Clinical Laboratory, Affiliated Hospital of Hainan Medical College, 31 Longhua Road, Haikou, 570100, Hainan, People's Republic of China,
Tumour Biol. 2014 Aug;35(8):7707-12. doi: 10.1007/s13277-014-2038-2. Epub 2014 May 8.
In the light of the relationship between the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and thyroid cancer (TC) exist objection, a meta-analysis of the MTHFR C677T polymorphism with thyroid cancer risk was performed. All the available studies were identified through a search of the PubMed, Embase, Web of Science, and Chinese Biomedical Literature Database (CBM) up to March 2014. The association between the MTHFR C677T polymorphism and thyroid cancer risk was conducted by odds ratios (ORs) and 95 % confidence intervals (95 % CIs). A total of five independent studies with 2,554 cases and 2,671 controls were included in our meta-analysis. Significant association was found between MTHFR C677T polymorphism and thyroid cancer risk in recessive model in overall populations (TT vs.
TC/CC: OR = 1.88, 95 % CI = 1.59-2.21, P = 0.00), but there was no association between MTHFR C677T polymorphism and thyroid cancer risk found in other four models in overall populations (T vs. C: OR = 1.25, 95 % CI = 0.96-1.62, P = 0.10; TT vs. CC: OR = 1.11, 95 % CI = 0.93-1.33, P = 0.26; TC vs. CC: OR = 1.23, 95 % CI = 0.84-1.82, P = 0.29; TT/TC vs. CC: OR = 1.28, 95 % CI = 0.89-1.84, P = 0.19). In the subgroup analysis base on the ethnicity, the results suggested that MTHFR C677T polymorphism was significantly associated with thyroid cancer risk both in Caucasian and Asian populations in recessive model: (Caucasians: TT vs.
TC/CC: OR = 2.28, 95 % CI = 1.11-4.67, P = 0.025; Asians: TT vs.
TC/CC: OR = 1.86, 95 % CI = 1.57-2.20, P = 0.00). In conclusions, our meta-analysis suggested that the MTHFR C677T polymorphism is associated with thyroid cancer both in Caucasians and Asians.
鉴于亚甲基四氢叶酸还原酶（MTHFR）C677T基因多态性与甲状腺癌（TC）之间的关系存在争议，我们对MTHFR C677T基因多态性与甲状腺癌风险进行了一项荟萃分析。通过检索截至2014年3月的PubMed、Embase、Web of Science和中国生物医学文献数据库（CBM），确定了所有可用的研究。通过比值比（OR）和95%置信区间（95%CI）来分析MTHFR C677T基因多态性与甲状腺癌风险之间的关联。我们的荟萃分析共纳入了5项独立研究，包括2554例病例和2671例对照。在总体人群的隐性模型中发现MTHFR C677T基因多态性与甲状腺癌风险存在显著关联（TT与TC/CC相比：OR = 1.88，95%CI = 1.59 - 2.21，P = 0.00），但在总体人群的其他四种模型中未发现MTHFR C677T基因多态性与甲状腺癌风险存在关联（T与C相比：OR = 1.25，95%CI = 0.96 - 1.62，P = 0.10；TT与CC相比：OR = 1.11，95%CI = 0.93 - 1.33，P = 0.26；TC与CC相比：OR = 1.23，95%CI = 0.84 - 1.82，P = 0.29；TT/TC与CC相比：OR = 1.28，95%CI = 0.89 - 1.84，P = 0.19）。在基于种族的亚组分析中，结果表明在隐性模型中，MTHFR C677T基因多态性在白种人和亚洲人群中均与甲状腺癌风险显著相关：（白种人：TT与TC/CC相比：OR = 2.28，95%CI = 1.11 - 4.67，P = 0.025；亚洲人：TT与TC/CC相比：OR = 1.86，95%CI = 1.57 - 2.20，P = 0.00）。总之，我们的荟萃分析表明，MTHFR C677T基因多态性在白种人和亚洲人中均与甲状腺癌相关。
Zotero 插件